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IMPORTANCE Dexamethasone initiated after the first week of life reduces the rate of death or
bronchopulmonary dysplasia (BPD) but may cause long-term adverse effects in very preterm
infants. Hydrocortisone is increasingly used as an alternative, but evidence supporting its
efficacy and safety is lacking.
OBJECTIVE To assess the effect of hydrocortisone initiated between 7 and 14 days after birth
on death or BPD in very preterm infants.
DESIGN, SETTING, AND PARTICIPANTS Double-blind, placebo-controlled randomized trial
conducted in 19 neonatal intensive care units in the Netherlands and Belgium fromNovember
15, 2011, to December 23, 2016, among preterm infants with a gestational age of less than 30
weeks and/or birth weight of less than 1250 g whowere ventilator dependent between 7 and
14 days of life, with follow-up to hospital discharge ending December 12, 2017.
INTERVENTIONS Infants were randomly assigned to receive a 22-day course of systemic
hydrocortisone (cumulative dose, 72.5 mg/kg) (n = 182) or placebo (n = 190).
MAIN OUTCOMES ANDMEASURES The primary outcomewas a composite of death or BPD
assessed at 36 weeks’ postmenstrual age. Twenty-nine secondary outcomes were analyzed
up to hospital discharge, including death and BPD at 36 weeks’ postmenstrual age.
RESULTS Among 372 patients randomized (mean gestational age, 26 weeks; 55%male), 371
completed the trial; parents withdrew consent for 1 child treated with hydrocortisone. Death
or BPD occurred in 128 of 181 infants (70.7%) randomized to hydrocortisone and in 140 of
190 infants (73.7%) randomized to placebo (adjusted risk difference, −3.6% [95% CI, −12.7%
to 5.4%]; adjusted odds ratio, 0.87 [95% CI, 0.54-1.38]; P = .54). Of 29 secondary outcomes,
8 showed significant differences, including death at 36 weeks’ postmenstrual age (15.5%with
hydrocortisone vs 23.7%with placebo; risk difference, −8.2% [95% CI, −16.2% to −0.1%];
odds ratio, 0.59 [95% CI, 0.35-0.995]; P = .048). Twenty-one outcomes showed
nonsignificant differences, including BPD (55.2%with hydrocortisone vs 50.0%with
placebo; risk difference, 5.2% [95% CI, −4.9% to 15.2%]; odds ratio, 1.24 [95% CI, 0.82-1.86];
P = .31). Hyperglycemia requiring insulin therapy was the only adverse effect reportedmore
often in the hydrocortisone group (18.2%) than in the placebo group (7.9%).
CONCLUSIONS AND RELEVANCE Amongmechanically ventilated very preterm infants,
administration of hydrocortisone between 7 and 14 days after birth, compared with placebo,
did not improve the composite outcome of death or BPD at 36 weeks’ postmenstrual age.
These findings do not support the use of hydrocortisone for this indication.
TRIAL REGISTRATION Netherlands National Trial Register Identifier: NTR2768
JAMA. 2019;321(4):354-363. doi:10.1001/jama.2018.21443
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B ronchopulmonary dysplasia (BPD) is a common seri-ouscomplicationofpretermbirth, affectingalmosthalfof infants born at gestational ages of less than 28
weeks.1,2 Infants with BPD are more likely to die early,3 and
thosewho survivehave an increased risk of long-termpulmo-
nary and neurodevelopmental morbidity.4,5
Pulmonary inflammation is an important risk factor in the
development of BPD, providing the rationale for treating at-
risk infantswith corticosteroids.6Until the early 2000s, dexa-
methasonewasusedwidelybecause randomizedclinical trials
showed that dexamethasone reduced the risk of death or
BPD.7,8 However, this benefit may be outweighed by an in-
creased risk of neurodevelopmental impairment.7 As a re-
sult, clinicians started using dexamethasone less frequently,
in lower doses, and at later postnatal ages.9,10 Furthermore,
international guidelines recommended investigatingwhether
hydrocortisone would be an effective and safe alternative to
dexamethasone.11,12
To date, hydrocortisone has been studied only as a pro-
phylactic treatment (ie, started at ≤7 days of life), and reports
conflict on the effect ondeathorBPD.7Althoughcurrentprac-
tice surveys show that corticosteroid treatment is almost ex-
clusively used after the first week of life,9,10 and hydrocorti-
sone treatment has already been implemented in many
neonatalunits across theworld, a clinical trial investigating the
efficacy and safety of hydrocortisone treatment initiated be-
tween 7 and 14 days after birth is lacking.9,13
This multicenter randomized clinical trial tested the hy-
pothesis that systemichydrocortisone treatment initiatedbe-
tween 7 and 14 days after birth in very preterm infants receiv-
ing mechanical ventilation decreased the incidence of death
or BPD at 36 weeks’ postmenstrual age.14
Methods
Study Design
This double-blind, placebo-controlled, superiority random-
ized trial was performed at 19 neonatal intensive care units in
theNetherlandsandBelgium.Thehumanresearchethics com-
mitteesateachparticipatingcenterapprovedthe trial.All study
sites were monitored by an independent clinical research as-
sociate. The study protocol appears in Supplement 1 and has
been previously published.14
Study Population
Infants were included after written informed consent was
obtained from both parents. Infants born at a gestational
age of less than 30 weeks and/or with a birth weight of less
than 1250 g who were ventilator dependent between 7 and
14 days’ postnatal age and at high risk of developing BPD
were eligible. High risk of developing BPD was defined as
having a respiratory index (product of mean airway pres-
sure and the fraction of inspired oxygen) equal to or greater
than 3.5 for more than 12 h/d for at least 48 hours. During
the initial months of the trial, participating centers noted
that many infants receiving ventilation and considered at
high risk of BPD had a respiratory index of less than 3.5 and
were treated with corticosteroids outside the trial. Based on
this feedback, the respiratory index threshold was reduced
to 3.0 and finally to 2.5 (in May 2012 and December 2012,
respectively) via approved protocol amendments. Infants
were ineligible if they had chromosomal defects or major
congenital malformations or had received corticosteroids
for improving lung function in the first week of life. Because
ethnic background affects the risk of death or BPD,15 ethnic-
ity as reported by the attending physician based on fixed
categories was collected.
Randomization
Eligible infants were randomly allocated in a 1:1 ratio to either
hydrocortisone or placebo, stratified by study center and ges-
tational age (<27 weeks or ≥27 weeks) and using randomly
permuted block sizes between 2 and 8. Multiple-birth infants
were randomized independently unless the parents or care-
givers explicitly requested that siblings were to be allocated
to the same treatment group. The randomization sequence
was generated electronically with Alea randomization soft-
ware (Alea Clinical/FormsVision). The hydrocortisone and
placebo vials appeared identical, and the investigators, care-
givers, and parents were blinded to group assignment.16
Intervention
Infants allocated to the intervention group were given
hydrocortisone sodium succinate, 5mg/kg per day in 4 doses
per day for 7 days, followed by 3.75 mg/kg per day in 3 doses
per day for 5 days, subsequently lowering the frequency by
1 dose every 5days. This resulted in 22days of treatmentwith
a cumulative dose of 72.5mg/kg. Infants allocated to the con-
trol group received aplacebo (mannitol) using adosing sched-
ule with volumes and duration similar to those of hydrocor-
tisone. The use of open-label hydrocortisone during the trial
was strongly discouraged but could be considered in infants
with severe and progressive pulmonary deterioration (respi-
ratory index >10 for more than 6 consecutive hours) or who
received at least 10 days of trial medication but did not show
an improvement inpulmonarycondition.Trialmedicationwas
stopped when open-label hydrocortisone was initiated.
Key Points
Question What is the effect of systemic hydrocortisone, initiated
between 7 and 14 days after birth, on death or bronchopulmonary
dysplasia among very preterm infants receiving mechanical
ventilation?
Findings In this randomized clinical trial that included 372 infants,
there was no significant difference in the composite outcome of
death or bronchopulmonary dysplasia at 36 weeks’ postmenstrual
age between the hydrocortisone and placebo groups (71% vs 74%,
respectively).
Meaning These findings do not support the practice of initiating
hydrocortisone between 7 and 14 days after birth to reduce the
risk of the composite outcome of death or bronchopulmonary
dysplasia in mechanically ventilated very preterm infants.
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Study Outcomes
The primary outcome was a composite of death or BPD at 36
weeks’ postmenstrual age. Patients were categorized as hav-
ing BPD if they required positive pressure support, required
supplemental oxygen with a fraction of inspired oxygen ex-
ceeding 0.30 (severe BPD), or had a fraction of inspired oxy-
gen of 0.22 to 0.29 and a failed oxygen reduction test (mod-
erateBPD).17,18 In5 infants, the indicatedoxygenreduction test
was not performed. For these infants, a committee of 3 inde-
pendent clinical experts masked to treatment allocation as-
sessed the severity of BPD diagnosis.
In addition to the components of the primary out-
come, the following prespecified secondary outcomes were
assessed: mortality at 28 days and at hospital discharge, BPD
at 28 days, failure to extubate at days 3, 7, 14, and 21, total
duration of mechanical ventilation and supplemental oxy-
gen, use of open-label hydrocortisone, hospital length of stay,
necrotizing enterocolitis, gastrointestinal bleeding, sponta-
neous intestinal perforation, intraventricular hemorrhage,
periventricular leukomalacia, retinopathy of prematurity,
hypertension, hyperglycemia, nosocomial infection (ie, sep-
sis, pneumonia, meningitis), patent ductus arteriosus, and
growth as assessed by body weight and head circumference
at 36 weeks’ postmenstrual age. In addition, long-term health
and developmental outcomes will be assessed at 2 years’ cor-
rected age but are not reported in this article. More details on
definitions can be found in the published statistical analysis
plan, available in Supplement 2.16
Suspected serious adverse drug reactions and serious ad-
verse events were reported to the data and safetymonitoring
board and the trial’s principal investigator.
Statistical Analysis
Previous studies comparing dexamethasone treatment initi-
atedbetween7and14daysafterbirthwithplacebo inverypre-
term infants undergoing mechanical ventilation have shown
a25%absolute riskdifference in theprimaryoutcomeofdeath
orBPD in favor of dexamethasone.19 Ideally, the treatment ef-
fect of hydrocortisone should be similar to dexamethasone to
consider it a good alternative. If safety is improved, a slightly
reduced treatment effect of hydrocortisonemight also change
clinical practice. For this reason, the target sample size of 175
patients in each treatment group was based on an estimated
probability of deathorBPDof0.60 in theplacebogroup, a 15%
absolute risk reduction with hydrocortisone treatment, 80%
power, anda2-tailed type I errorof .05.Anticipating 10%drop-
out, we aimed to include 200 infants in each group.
Analyses were performed according to the intention-to-
treat principle including all randomized infants regardless of
protocol deviations.Crudeabsolute riskdifferences andcrude
odds ratios were calculated for the primary outcome and its
components. For the primary outcome, a generalized linear
modelwith a binomial distribution and identity linkwas used
to estimate the absolute risk difference adjusted for the strati-
fication factors. A logistic regressionmodel correcting for the
stratification factors of gestational age and study center was
used to estimate the adjusted odds ratio for the primary out-
come. To check the robustness of the main results, we per-
formed preplanned sensitivity analyses including per-
protocol (includingonly infants treatedaccording to the study
protocol) and as-treated analyses (including infants based on
actual treatment received), use of an alternative BPD defini-
tion (infants receivingpositivepressureorhigh flowwith room
air, classified as mild BPD), a generalized estimating equa-
tionsmodel to account for clusteringof outcomeswithinmul-
tiple births, andexaminationof potential confounding andef-
fect modification using a multivariable model including
treatment and gestational age, chorioamnionitis,20 respira-
tory indexat randomization,21 sex,22andmultiplebirth23aspre-
selected baseline risk factors for BPD and subgroup analyses.
Preplanned subgroup analyses based on gestational age (<27
weeks vs ≥27 weeks), chorioamnionitis (yes vs no), respira-
tory indexatrandomization(less thanorequal tovsgreater than
themedian), sex (malevs female),multiplebirth (singlevsmul-
tiple), and study center steroid preference (hydrocortisone vs
dexamethasone)were performed and statistically testedwith
interaction effects of the specific subgroup and treatment in
logistic regressionmodels.Aposthocmixed-effects logistic re-
gressionmodelwith site as randomeffectwasperformedasan
additional sensitivity analysis to check the robustness of the
preplannedmain analysis of the composite outcome.
To allow more insight into the observed differential
death rates at 36 weeks postmenstrual age, post hoc sensitiv-
ity and subgroup analyses were performed.24,25 First, we
studied the treatment effect in the per-protocol population.
Second, we studied the treatment effect adjusted for postu-
lated risk factors for death: gestational age,2 small for gesta-
tional age (<10th percentile of the Fenton growth charts),26,27
severity of lung disease as measured by respiratory index,21
sex,22 and multiple birth.23 Third, exploratory subgroup
analyses were performed using these risk factors. Fourth,
time to death was estimated for both treatment groups using
a Kaplan-Meier survival curve and compared with a log-rank
test. The proportionality assumption was established by
graphical examination and use of a time-dependent covariate
in a Cox model.
The effect of hydrocortisone compared with placebo on
the occurrence of short-term secondary outcomes was ana-
lyzed using linear, logistic, or competing risk (with death
occurring before the event of interest considered a competing
risk) regression, as appropriate. Time to event was calculated
as the time between randomization and the event of interest,
death, or discharge home (censoring event), whichever
occurred first.
In case ofmissing data, every attemptwas undertaken to
retrieve the data fromboth levels III and II (referral) hospitals
because many infants were transferred back to referral hos-
pitals once clinically stable. Because theprimaryoutcomeand
most secondary outcomes were assessed before hospital dis-
charge, we anticipated no or minimal missing values.
For all treatment effect estimators, 95%confidence inter-
vals are presented; all analyseswere performedusing 2-sided
tests andP<.05was regardedas statistically significant.Noad-
justments for multiple comparisons were made, so second-
ary outcome analyses should therefore be interpreted as ex-
ploratory.For statistical analysis andcomputing,weusedSPSS
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version 24 (IBM Corp) and R version 3.4.3 (R Foundation for
Statistical Computing).
An independent data and safety monitoring board con-
ducted interim analyses for safety outcomes every 3 months
during the first 2 years of the study. After this period, the fre-
quency of safety monitoring was reduced to thrice and then
twice annually. Thedata and safetymonitoring board advised
on whether the trial should be stopped for safety concerns or
futility according to thepredefinedcharter.16Hence, therewas
no α spending associated with the interim analyses.
Results
Study Population
Between November 15, 2011, and December 23, 2016, 7065
infants were screened and 372 infants were randomized,
182 to the hydrocortisone group and 190 to the placebo
group (Figure 1). Parents of 1 infant in the hydrocortisone
group withdrew consent and this infant was excluded from
the intention-to-treat analyses. Because the dropout rate was
lower than expected, the minimum required sample size
(n = 350) for the primary outcome analysis was attained in
December 2016 and further inclusion was stopped.
Follow-up to hospital discharge ended on December 12, 2017.
Baseline characteristics of mothers and infants were broadly
similar in both groups, with some differences in birth weight,
proportion of infants small for gestational age, and multiple
births (Table 1). Of the 70 multiple births in the hydrocorti-
sone group, 33 siblings participated in the trial, of whom 29
were allocated to the same treatment group per parental
request. In the placebo group, 22 siblings from 54 multiple
births participated in the trial, of whom 12 were allocated to
the same treatment group.
In the per-protocol analysis for the primary outcome, 173
infantswere analyzed in the hydrocortisone group and 162 in
theplacebogroup. In theas-treatedanalysis, a total of 288par-
ticipants were analyzed as hydrocortisone treated vs 80 in-
fants in the placebo group (eFigure in Supplement 3).
Primary Outcome
All participating infants were assessed for the primary out-
come. In total, 73 infants (20%) died and 195 survivors (53%)
were diagnosed as having BPD. The observed rate of death or
BPDwas 70.7% (128/181 infants) in the hydrocortisone group
and 73.7% (140/190 infants) in the placebo group. After ad-
justment for stratification factors, the risk difference be-
tween hydrocortisone and placebo treatment for the primary
outcome was −3.6% (95% CI, −12.7% to 5.4%) and the ad-
justedodds ratiowas0.87 (95%CI,0.54-1.38;P = .54) (Table2).
Secondary Outcomes
Therewerenomissingdata for secondaryoutcomesexcept for
growth variables at 36 weeks’ postmenstrual age (Table 2).
The rateofBPDwasnot significantlydifferentbetween the
hydrocortisone group (55.2%) and the placebo group (50.0%)
(crude risk difference, 5.2% [95% CI, −4.9% to 15.2%]; crude
odds ratio, 1.24 [95%CI, 0.82-1.86];P = .31) (Table 2). The rate
Figure 1. Recruitment, Randomization, and Participant Flow in a Trial of Hydrocortisone vs Placebo
Among Very Preterm Infants ReceivingMechanical Ventilation
7065 Infants assessed for eligibility
372 Randomized
182 Randomized to receive hydrocortisone
181 Received hydrocortisone as randomized
1 Did not receive hydrocortisone
(died prior to first dose )
181 Included in primary analysis of death or
bronchopulmonary dysplasia at 36 wk 
postmenstrual age
1 Excluded (withdrew consent)
1 Missing status for death or bronchopulmonary 
dysplasia at 36 wk postmenstrual age
(withdrew consent)
190 Included in primary analysis of death or 
bronchopulmonary dysplasia at 36 wk
postmenstrual age
6693 Excluded
6519 Did not meet inclusion criteria
162 Parents declined to participate
5911 Did not undergo mechanical ventilation
between 7th and 14th days of life with
respiratory index ≥2.5a
608 Died before 7th day of life
12 Other reasons
190 Randomized to receive placebo
188 Received placebo as randomized
2 Did not receive placebo
1 Died prior to first dose
1 Physician decision not to start
a Respiratory index was defined as
mean airway pressure × fraction of
inspired oxygen.
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of death, however, was significantly decreased in the hydro-
cortisonegroup (28/181 infants [15.5%]) comparedwith thepla-
cebo group (45/190 infants [23.7%]) (crude risk difference,
−8.2% [95%CI, −16.2% to−0.1%]; crudeodds ratio, 0.59 [95%
CI,0.35-0.995];P = .048).Reportedcausesofdeathwere simi-
lar between the 2 groups (eTable 1 in Supplement 3).
Analyses of theprespecified secondaryoutcomes showed
that the lower death rate in the hydrocortisone group at 36
weeks’ postmenstrual age was no longer significantly differ-
ent at hospital discharge (hydrocortisonevsplacebo, 19.9%vs
28.4%; risk difference, −8.5% [95%CI, −17.1% to0.2%]; crude
odds ratio, 0.63 [95%CI, 0.39-1.01]; P = .06) (Table 2). No sig-
nificant difference in the distribution of severity of BPD was
seen between treatment groups.
Significantlymore infantswere successfully extubated in
thehydrocortisone than in theplacebo grouponday 3 (84.4%
vs 92.9%; crude risk difference, −8.5% [95% CI, −15.3% to
−1.9%]; crudeodds ratio,0.41 [95%CI,0.21-0.83];P = .01), day
7 (54.4% vs 78.1%; crude risk difference, −23.7% [95% CI,
−32.9% to −13.8%]; crude odds ratio, 0.34 [95% CI, 0.21-
0.54];P < .001), andday 14 (33.7%vs 51.2%; crude risk differ-
ence,−17.5%[95%CI,−27.5%to−6.9%]; crudeodds ratio,0.49
[95%CI,0.31-0.76];P = .001) after initiating therapy (Table 2).
The incidenceofhyperglycemia requiring insulin therapywas
higher in the hydrocortisone group compared with the pla-
cebo group (18.2% vs 7.9%; crude risk difference, 10.3% [95%
CI, 3.5%-17.3%]; sub–hazard ratio, 2.44 [95% CI, 1.34-4.47];
P = .004). There was a significantly lower rate of pneumonia
(24.9%vs 33.7%; crude riskdifference, −8.8% [95%CI, −17.5%
to0.0%]; sub–hazardratio,0.68[95%CI,0.47-0.997];P = .048)
and significantly greater meanweight at 36 weeks’ postmen-
strualage (2235gvs2125g;P = .03) in thehydrocortisonegroup
comparedwith theplacebogroup (Table 2). Therewereno sig-
nificant differences between the groups for other secondary
outcomes. The rate of open-label glucocorticoiduse in thehy-
drocortisonegroupwas28.2%comparedwith56.8%inthepla-
cebo group (crude risk difference, −28.7% [95% CI, −37.8% to
−18.7%]; sub–hazard ratio,0.36 [95%CI,0.26-0.50];P < .001).
Adverse Events
Themost common adverse events related to preterm birth in
thehydrocortisoneandplacebogroups, respectively,werepat-
ent ductus arteriosus (39.8% vs 41.1%), clinical or culture-
proven sepsis (50.3% vs 58.4%), retinopathy of prematurity
higher than grade 2 (24.3%vs 22.1%), and pneumonia (24.9%
vs 33.7%). No serious adverse drug reactions were reported,
and the observed rate of severe adverse events and number
of studymedicationprotocol deviationswere lowand similar
in treatment groups (eTable 2 in Supplement 3).
Prespecified Sensitivity and Subgroup Analyses
Neither theprespecified sensitivity nor subgroupanalyses re-
vealed a significant effect of hydrocortisone on the primary
composite outcome (eTable 3 and eTable 4 in Supplement 3).
Post Hoc Analyses
Thepost hocmixed-effects logistic regressionmodelwith site
as random effect showed similar results for the treatment ef-
fect on the primary composite outcome (adjusted odds ratio,
0.82; 95% CI, 0.51-1.32; P = .41).
The post hoc per-protocol analysis of the primary out-
come component of death showed a similar reduction as the
intention-to-treat analysis (eTable 5 in Supplement 3). Adjust-
ment for risk factors for death showed no substantive change
in treatment effect (adjusted odds ratio, 0.56; 95% CI, 0.32-
0.96;P = .03). Post hoc subgroup analyses did not find differ-
ential treatment effects across subgroups, except for the
Table 1. Maternal and Infant Characteristics
Characteristics
Hydrocortisone
(n = 182)
Placebo
(n = 190)
Maternal characteristicsa
Age, median (IQR), y 30 (27-34) 30 (27-34)
Ethnic origin, No. (%)b
Caucasian 138 (75.8) 140 (73.7)
Mediterranean 12 (6.6) 10 (5.2)
African 13 (7.1) 22 (11.6)
Asian 7 (3.9) 11 (5.8)
Latin American 5 (2.8) 1 (0.5)
Unknown 7 (3.8) 6 (3.2)
Clinical chorioamnionitis,
No. (%)c
51 (28.0) 53 (27.9)
Cesarean
delivery, No. (%)
98 (53.8) 111 (58.4)
Antenatal corticosteroids
(any), No. (%)
159 (87.4) 172 (90.5)
Pregnancy-induced
hypertension, No. (%)
33 (18.1) 45 (23.6)
Infant characteristics
Gestational age,
median (IQR), wk
25.4 (24.9-26.4) 25.6 (24.7-26.4)
Birth weight,
median (IQR), g
775 (644-865) 710 (629-810)
Male sex, No. (%) 96 (52.8) 109 (57.4)
Small for gestational age,
No. (%)d
26 (14.3) 38 (20.0)
Multiple birth, No. (%) 70 (38.5) 54 (28.4)
Apgar 5-min score,
median (IQR)
7 (6-8) [n=180] 7 (6-8)
Duration of invasive
respiratory support
before randomization,
median (IQR), d
9 (7-11) 9 (7-11)
Age at randomization,
median (IQR), d
10 (8-13) 11 (9-13)
Fraction of inspired oxygen
at randomization,
median (IQR)
0.35 (0.30-0.45) 0.34 (0.29-0.40)
Respiratory index
at randomization,
median (IQR)e
4.3 (3.3-5.3) 3.9 (3.1-5.0)
Abbreviation: IQR, interquartile range.
a Maternal characteristics have been summarized at the infant level (ie, women
were countedmultiple times if they hadmultiple infants).
b Reported by attending physicians and selected from fixed categories.
c Clinical chorioamnionitis was defined as maternal fever without other cause
(eg, urinary tract infection or pneumonia), prenatal antibiotic use without
source of infection other than chorioamnionitis, or preterm premature rupture
of membranes.
dDefined as less than the 10th percentile on the Fenton growth chart.
e Respiratory index was defined as mean airway pressure × fraction of
inspired oxygen.
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subgroup of infants born at a gestational age of less than 27
weeks, which showed a reduced death rate in the hydrocorti-
sone group (14.1%) comparedwith the placebo group (26.4%)
(crude riskdifference,−12.3%[95%CI,−21.0%to−3.3%]; crude
relative risk, 0.53 [95%CI, 0.33-0.86]; P = .03 for interaction)
(eTable 6 in Supplement 3). Kaplan-Meier curves for survival
until 36 weeks’ postmenstrual age were not significantly dif-
ferent (log-rank test, P = .06) (Figure 2).
Discussion
Thismulticenter randomized trial foundno significant differ-
ence in the primary composite outcome of death or BPD at 36
weeks’ postmenstrual age among infants randomized to hy-
drocortisone compared with those randomized to placebo at
7 to 14days.Hydrocortisonehasmainly been studied as apro-
phylactic treatment started in the first days of life indepen-
dentof thepatient’spulmonaryconditionandtreatment.Some
of these trials, such as the PREMILOC trial, showed a benefit
on the combined outcome of death or BPD, while others did
not.7,28 With the exception of a small pilot study assessing
changes in brain volume,29 no other randomized trial has ad-
dressed the effect of hydrocortisone initiated between 7 and
14 days after birth on death or BPD. In contrast to the finding
of this trial, a systematic review on dexamethasone treat-
ment initiated after the first week of life found a reduction in
the composite outcome of death or BPD, with the association
mainly driven by a reduction in BPD.8 The absence of a clear
effect of hydrocortisone on the primary outcome component
of BPD in this studymay have several explanations. First, hy-
drocortisone may have a different effect on lung inflamma-
tion thandexamethasone.Hydrocortisone targetsboth theglu-
cocorticoid and mineralocorticoid receptors, whereas
dexamethasone solely targets glucocorticoid receptors. This
dual receptor activitymay cause less brain toxicity30 butmay
also result in less potency to reduce pulmonary inflamma-
tion. Second, the administered cumulative dose of hydrocor-
tisone usedmay have been too low to affect the development
ofBPD.This explanation is less likely, as ameta-analysis of the
dexamethasone trials initiated after the first week of life
showed that a cumulative dose of more than 2 mg/kg re-
sulted ina significantbeneficial effecton theoutcomeofdeath
orBPD,19andtheadministeredcumulativehydrocortisonedose
in this trial was equivalent to a dexamethasone dose of
2.9mg/kg. Third, the higher use of open-label corticosteroids
in the placebo groupmay have diluted a possible effect of hy-
drocortisone on BPD in surviving children. The rate of open-
labeluseofcorticosteroids in this trialwassimilar tomostdexa-
methasone trials, so this also seems an unlikely explanation
for the apparent difference in effect on BPD between hydro-
cortisone and dexamethasone.31
Exploratory analysis showed that hydrocortisonemay re-
duce the risk of the primary outcome component of death at
36 weeks’ postmenstrual age. However, this finding must be
interpretedcautiouslyandconsideredexploratory,as thestudy
was not powered to adjust for multiple secondary outcome
comparisons. Furthermore, although the effect size changed
little, the observed reduction did not remain statistically sig-
nificant up to hospital discharge. For this reason, a careful as-
sessment of theplausibility of this findingusingpost hoc sen-
sitivity analyses was performed.24,25 These analyses support
the robustness of the hydrocortisone effect on death at 36
weeks’ postmenstrual age. The exploratory observationof re-
duced risk of death is consistent with studies assessing pro-
phylacticuseofhydrocortisone.Ameta-analysisof these stud-
ies showed that the reduced risk of the outcome of death or
BPD in favor of hydrocortisonewasmainlydrivenby the com-
ponent of death at hospital discharge.7 Consistent with this
study, themeta-analysis revealedno significant associationof
prophylactic hydrocortisone with BPD.
Therewas no significant difference in causes of death be-
tween groups, including pulmonary deterioration. Subclini-
cal adrenocortical insufficiencyhas been reported in sick pre-
terminfants, especially thosewithagestational ageof less than
28 weeks.32 Supplementation with hydrocortisone might re-
duce the risk of mortality in this high-risk population by im-
proving pulmonary andhemodynamic stability anddamping
the systemic inflammatory response.32The finding that the re-
duced risk of death was larger in the group born before 27
weeks’ gestation supports this suggested mechanism.
The results of this trial may have important implications
for clinical practice. Currently, the main reasons for clini-
cians to treat preterm infants with corticosteroids are to ex-
pedite weaning from mechanical ventilation and reduce the
risk of BPD. Treatment is usually started late in the disease
course, ie, after several weeks ofmechanical ventilation, and
despite the lack of randomized evidence to date, many cen-
ters have changed from treating with dexamethasone to
hydrocortisone.9,13 These results suggest that hydrocorti-
sone facilitates extubation but, in contrast to dexametha-
sone, does not reduce BPD. Therefore, this finding does not
support the use of hydrocortisone for this indication. Yet hy-
drocortisone initiated between 7 and 14 days after birth may
reduce mortality, and this benefit is not outweighed by an
Figure 2. Overall CumulativeMortality FromRandomization
to 36Weeks’ Postmenstrual Age
0
No. at risk
0 28 42 56 70 84
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10
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Median follow-up to 36 weeks’ postmenstrual age was 61 days (interquartile
range, 50-67 days) for hydrocortisone and 58 days (interquartile range,
44-67 days) for placebo.
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increase in short-termmorbidity, as reportedbyprevious stud-
ies initiating corticosteroid treatment before or after the first
week of life.7,8 Although many infants in this trial experi-
enced adverse effects of preterm birth, the only adverse ef-
fect ascribed specifically tohydrocortisone treatmentwashy-
perglycemia requiring insulin. Information on short-term
outcomes is insufficient to assess the long-term safety of hy-
drocortisone treatment. Therefore, follow-upof the study co-
hort, including assessment of neurodevelopmental outcome
at 24 months’ corrected age, is currently under way.
Limitations
Thisstudyhasseveral limitations.First, this studywasnotpow-
eredtodetect smallerdifferences in theprimaryoutcome.Con-
sidering thatprevious studies showed thatdexamethasone re-
duced the rate of death or BPD almost 25% compared with
placebo,19 it is unlikely that differences smaller than 15% fa-
voring hydrocortisone treatment would change current prac-
tice. Second, thehigheruseofopen-label corticosteroids in the
placebo groupmayhavediluted apossible effect of hydrocor-
tisone on BPD in the surviving children. Third, lowering the
respiratory index in the first year of the study could have af-
fected the sample size calculation by including patients with
a lower a priori risk of the primary outcome.However, the ob-
served high rate of the primary outcome in the placebo group
does not support this reasoning.
Conclusions
Among mechanically ventilated very preterm infants, ad-
ministration of hydrocortisone between 7 and 14 days after
birth, compared with placebo, did not improve the composite
outcome of death or BPD at 36 weeks’ postmenstrual age.
These findings do not support the use of hydrocortisone for
this indication.
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